The current socioeconomic and regulatory landscape of immune effector cell therapies

The current socioeconomic and regulatory landscape of immune effector cell therapies

Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent a transformative approach to cancer treatment, harnessing the immune system to target and eradicate malignant cells....

Full description

Saved in:

Bibliographic Details
Main Authors:	Chiranjeevi Sainatham, Devvrat Yadav, Aravind Dilli Babu, Jayanth Reddy Tallapalli, Sai Gautham Kanagala, Evgenii Filippov, Franco Murillo Chavez, Nausheen Ahmed, Forat Lutfi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Series:	Frontiers in Medicine
Subjects:	CAR T-cell therapy immune effector cell therapy regulatory environment for cellular therapeutics bispecific antibodies (BsAbs) TILs (tumor infiltrating lymphocytes)
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2024.1462307/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

T cell margination: investigating the detour of T cells following forimtamig treatment in humanized mice
by: Nils O’Brien, et al.
Published: (2025-12-01)

Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01)

A pivotal decade for bispecific antibodies?
by: Marlena Surowka, et al.
Published: (2024-12-01)

The state of the art of bispecific antibodies for treating human malignancies
by: Shuhang Wang, et al.
Published: (2021-08-01)

Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
by: Hang Ke, et al.
Published: (2024-11-01)

CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts
by: Anaïs Jiménez-Reinoso, et al.
Published: (2024-12-01)

Regional and intratumoral adoptive T-cell therapy
by: I. Olivera, et al.
Published: (2024-12-01)

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report
by: G. Menardi, et al.
Published: (2025-01-01)

Advances and prospects in tumor infiltrating lymphocyte therapy
by: Xu Qiu, et al.
Published: (2024-11-01)

A GD Type of Cancel Culture
by: W.K. Lim, et al.
Published: (2024-12-01)

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment
by: Rahul Navab, et al.
Published: (2025-01-01)

Tertiary lymphoid structure-related immune infiltrates in NSCLC tumor lesions correlate with low tumor-reactivity of TIL products
by: Suzanne M. Castenmiller, et al.
Published: (2024-12-01)

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
by: Joseph Sassine, et al.
Published: (2025-01-01)

Recognition of a Fungal Effector Potentiates Pathogen‐Associated Molecular Pattern‐Triggered Immunity in Cotton
by: Lifan Sun, et al.
Published: (2025-01-01)

Corrigendum: Editorial: Antiviral monoclonal antibody therapies
by: Catalina Florez, et al.
Published: (2025-02-01)

Editorial: Antiviral monoclonal antibody therapies
by: Catalina Florez, et al.
Published: (2024-10-01)

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report
by: Chiara Bernardi, et al.
Published: (2024-11-01)

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement
by: Guido Lancman, et al.
Published: (2024-11-01)

Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
by: Antonio Tapia-Galisteo, et al.
Published: (2024-12-01)

Algorithms for Effector Prediction in Plant Pathogens and Pests: Achievements and Current Challenges
by: César De los Santos-Briones, et al.
Published: (2024-10-01)

Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
by: Jennifer L. Schwedler, et al.
Published: (2024-12-01)

Role of Verticillium dahliae effectors in interaction with cotton plants
by: Lingling Yang, et al.
Published: (2025-01-01)

Subverting <i>Attachment</i> to Prevent <i>Attacking</i>: Alteration of Effector Immune Cell Migration and Adhesion as a Key Mechanism of Tumor Immune Evasion
by: Marta Mastrogiovanni, et al.
Published: (2024-10-01)

DARPin-fused T cell engager for adenovirus-mediated cancer therapy
by: Patrick C. Freitag, et al.
Published: (2024-09-01)

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers
by: Ammelie Svea Boje, et al.
Published: (2024-12-01)

Analyzing functional heterogeneity of effector cells for enhanced adoptive cell therapy applications
by: AC. Kiel Rasmussen, et al.
Published: (2024-12-01)

The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy
by: Amandine Decroos, et al.
Published: (2024-11-01)

Elevated LIF and JAK-STAT activation drive severe COVID-19 in myeloma patients receiving the BCMA-CD3 bispecific antibody Elranatamab
by: Ziping Li, et al.
Published: (2025-01-01)

Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions
by: Jianhua Ding, et al.
Published: (2024-12-01)

Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy
by: Yishen Tian, et al.
Published: (2025-04-01)

Mesenchymal stem cells and their exosomes mitigate osteoarthritis by restoring the balance between proinflammatory Teffs and Tregs
by: Tianhao Liu, et al.
Published: (2024-11-01)

A comprehensive two-hybrid analysis to explore the Legionella pneumophila effector–effector interactome
by: Harley O'Connor Mount, et al.
Published: (2024-12-01)

Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
by: Zhijuan Ai, et al.
Published: (2025-01-01)

Characterizing immune biomarkers and effector CD8+ T-cell exhaustion in pancreatic adenocarcinoma via single-cell RNA sequencing profiling
by: Rawaa AlChalabi, et al.
Published: (2025-01-01)

Multi-omics approaches define novel aphid effector candidates associated with virulence and avirulence phenotypes
by: Peter Thorpe, et al.
Published: (2024-11-01)

Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system
by: Christina Völzke, et al.
Published: (2024-12-01)

Injection site reaction to teclistamab in a patient with multiple myeloma
by: Isabel C. Yoon, BS, et al.
Published: (2025-02-01)

eEF-2K Deficiency Boosts the Virus-Specific Effector CD8<sup>+</sup> T Cell Responses During Viral Infection
by: Liqing Wang, et al.
Published: (2024-12-01)

Network-based pharmacological examination of the potential effector mechanisms of Achyranthes bidentata on osteoarthritis treatment
by: Junfeng WANG, et al.
Published: (2020-12-01)